Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PfLSA-3-rec + Montanide ISA 720
- Development stage
- Unknown
- Lead developer
- Institut Pasteur
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
PfLSA-3-rec + Montanide ISA 720 is a malaria vaccine candidate composed of a recombinant *Plasmodium falciparum* liver stage antigen 3 (PfLSA-3) formulated with the adjuvant Montanide ISA 720. The vaccine aims to induce an immune response against the liver stage of *P. falciparum*, potentially preventing malaria infection. Montanide ISA 720 is a squalene-based water-in-oil emulsion adjuvant known to enhance both antibody and cellular immune responses by forming a depot at the injection site and promoting slow antigen release[1][4][8]. The combination has been evaluated in early-phase clinical trials for safety, immunogenicity, and efficacy in malaria prevention[1][4]. Institut Pasteur has been involved in its development[1].
- Other names
- PfLSA-3-rec with Montanide ISA 720 as adjuvantPfLSA3-rec with Montanide ISA 720 as adjuvantPfLSA 3-rec with Montanide ISA 720 as adjuvant
02
Targets
LSA-3 (Plasmodium falciparum liver-stage antigen 3)
Beyond the preview
Go deeper on PfLSA-3-rec + Montanide ISA 720.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PfLSA-3-rec + Montanide ISA 720.